PT  - JOURNAL ARTICLE
AU  - Conal Hayton
AU  - Fayez Elsawy
AU  - Theresa Garfoot
AU  - Colm Leonard
AU  - Pilar Rivera-Ortega
AU  - John Blaikley
AU  - Nazia Chaudhuri
TI  - Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre
AID  - 10.1183/13993003.congress-2019.PA1728
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA1728
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA1728.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA1728.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Introduction: Immunosuppression plays an integral role in treatment of non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD), however use may be limited by side effects.Aim: To report the safety and tolerability of second-line immunosuppression use in non-IPF ILD at a tertiary centre.Methods: Patients with an MDT diagnosis of ILD other than IPF who had received at least one course of second-line immunosuppression between December 2009 and May 2018 were identified. Retrospective case note review was performed to identify adverse events (AEs).Results: 99 patients (45% male, mean age 60±10) received treatment with at least one second-line immunosuppressant. Diagnoses were; nonspecific interstitial pneumonia (28.3%), hypersensitivity pneumonitis (22.2%), sarcoid (17.2%), connective tissue disease related ILD (18.2%), unclassifiable ILD (11.1%), cryptogenic organising pneumonia (2.0%), acute interstitial pneumonitis (1.0%). Table 1 details the immunosuppressants used, number of patients reporting AEs and discontinuation rate. A total of 95 AEs were reported. The most commonly reported AEs across all treatments were abnormal liver function tests (18.9%), infection (15.8%) and tiredness (13.7%).Conclusion: Tolerability of immunosuppression was variable with a higher discontinuation rate amongst patients treated with azathioprine compared to other forms of immunosuppression.View this table:Table 1. FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1728.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).